High‐grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging
- 15 June 2016
- journal article
- research article
- Published by Wiley in Proteomics
- Vol. 16 (11-12) , 1802-1813
Abstract
The combination of high heterogeneity, both intratumoral and intertumoral, with their rarity has made diagnosis, prognosis of high‐grade sarcomas difficult. There is an urgent need for more objective molecular biomarkers, to differentiate between the many different subtypes, and to also provide new treatment targets. Mass spectrometry imaging (MSI) has amply demonstrated its ability to identify potential new markers for patient diagnosis, survival, metastasis and response to therapy in cancer research. In this study, we investigated the ability of MALDI‐MSI of proteins to distinguish between high‐grade osteosarcoma (OS), leiomyosarcoma (LMS), myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) (Ntotal = 53). We also investigated if there are individual proteins or protein signatures that are statistically associated with patient survival. Twenty diagnostic protein signals were found characteristic for specific tumors (p ≤ 0.05), amongst them acyl‐CoA‐binding protein (m/z 11 162), macrophage migration inhibitory factor (m/z 12 350), thioredoxin (m/z 11 608) and galectin‐1 (m/z 14 633) were assigned. Another nine protein signals were found to be associated with overall survival (p ≤ 0.05), including proteasome activator complex subunit 1 (m/z 9753), indicative for non‐OS patients with poor survival; and two histone H4 variants (m/z 11 314 and 11 355), indicative of poor survival for LMS patients.Keywords
Funding Information
- COMMIT
- Cyttron II
- ZonMW Zenith project Imaging Mass Spectrometry-Based Molecular Histology: Differentiation and Characterization of Clinically Challenging Soft Tissue Sarcomas (93512002)
- Marie Curie Action of the European Union (331866)
This publication has 43 references indexed in Scilit:
- International expert opinion on patient-tailored management of soft tissue sarcomasEuropean Journal of Cancer, 2014
- Comprehensive Identification of Proteins from MALDI ImagingMolecular & Cellular Proteomics, 2013
- Antiangiogenic approach in soft-tissue sarcomasExpert Review of Anticancer Therapy, 2013
- Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regionsAnnals of Oncology, 2012
- Advances in sarcoma genomics and new therapeutic targetsNature Reviews Cancer, 2011
- Peptide and protein imaging mass spectrometry in cancer researchJournal of Proteomics, 2010
- Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneityThe Journal of Pathology, 2010
- Molecular imaging by mass spectrometry — looking beyond classical histologyNature Reviews Cancer, 2010
- Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate TissueClinical Cancer Research, 2009
- Imaging mass spectrometryMass Spectrometry Reviews, 2007